Tamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrogen receptor-positive breast cancer, but markers predictive of treatment failure have not been identified. Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy. An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers. Ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and invasion in vitro, and its expression is increased in both preinvasive and invasive primary breast cancer. The HOXB13:IL17BR expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.
Introduction
). However, 25% of ERϩ/PRϩ tumors, 66% of ERϩ/PRϪ cases, and 55% of ERϪ/PRϩ cases fail to respond, or develop early resistance to tamoxifen, through mechanisms Tamoxifen is the antiestrogen agent most frequently prescribed in women with both early-stage and metastatic hormone recepthat remain largely unclear (Clarke et al., 2003; Nicholson et al., 2003; Osborne and Schiff, 2003) . Currently, no reliable means tor-positive breast cancer (reviewed in Clarke et al., 2003; Jordan, 2002) . In the adjuvant setting, tamoxifen therapy results in exist that allow the identification of patients who are at risk of tumor recurrence in the setting of adjuvant tamoxifen monothera 40%-50% reduction in the annual risk of recurrence, leading to a 5.6% improvement in 10-year survival in lymph node-negative apy. In such patients, the use of alternative hormonal therapies, such as the aromatase inhibitors letrozole and anastrozole (Buzdar, patients, and a corresponding 10.9% improvement in nodepositive patients (EBCTCG, 2001) . Tamoxifen is thought to act 1998; Ellis et al., 2001; Goss et al., 2003) , chemotherapeutic agents (Colleoni et al., 2003a) , or inhibitors of other signaling pathways, primarily as a competitive inhibitor of estrogen binding to estrogen receptor (ER), and it has no effect on tumor cells lacking such as trastuzmab and gefitinib (Atalay et al., 2003; Lichtner, 2003; Morris, 2002; Nicholson et al., 2003 ; Osborne and Schiff, ER expression. The absolute levels of ER expression, as well as those of the progesterone receptor (PR, an indicator of a 2003), might improve clinical outcome. Therefore, the ability to accurately predict tamoxifen treatment outcome should signififunctional ER pathway), are currently the best predictors of tamoxifen response in the clinical setting (Bardou et al., 2003;  cantly advance the management of early-stage breast cancer.
S I G N I F I C A N C E
The majority of breast cancers express estrogen receptor (ER), and most patients with ER-positive tumors are treated with adjuvant tamoxifen therapy. Approximately 40% of ERϩ breast cancers fail to respond or eventually develop resistance to tamoxifen, leading to disease progression. Current clinicopathological features including tumor stage and grade, and ERBB2 and EGFR expression fail to accurately identify individuals who are at risk for tumor recurrence. Our results demonstrate that a simple two-gene expression ratio of HOXB13 to IL17BR accurately predicts tumor recurrence in the setting of adjuvant tamoxifen monotherapy. Furthermore, the association of HOXB13 overexpression with poor clinical outcome and with enhanced cell invasiveness in vitro raises the possibility that it may play a role in breast cancer progression. Here, we performed a genome-wide microarray analysis archived primary biopsies. The resulting expression dataset was first filtered based on overall variance of each gene, with the top of hormone receptor-positive invasive breast tumors from 60 patients treated with adjuvant tamoxifen alone, leading to the 5,475 high-variance genes (75 th percentile) selected for further analysis. Using this reduced dataset, a t test was performed on identification of a two-gene expression ratio that is highly predictive of clinical outcome. This expression ratio can be readily each gene comparing tamoxifen nonrecurrences and recurrences, leading to the identification of 19 differentially expressed adapted to PCR-based analysis of standard formalin-fixed paraffin-embedded (FFPE) clinical specimens, which we demongenes at the p value cutoff of 0.001 ( Figure 1A ; Supplemental Table S2 ). The probability of selecting this many or more differstrated in an independent set of 20 patients with FFPE tissues. Further, we demonstrate that the homeobox gene HOXB13 entially expressed genes by chance was estimated to be 0.04 by randomly permuting the patient class with respect to treatment (Zeltser et al., 1996) , whose overexpression is associated with a poor outcome, confers invasive properties following ectopic outcome and repeating the t test procedure 2,000 times. This analysis thus demonstrated the existence of statistically signifiexpression in a nontransformed mammary epithelial cell line. Our results provide a simple molecular marker of clinical outcant differences in gene expression between the primary breast cancers of tamoxifen nonrecurrences and recurrences. come in ER-positive early-stage breast cancer and may provide insight into molecular mechanisms underlying tamoxifen resisTo refine our analysis to the tumor cells and circumvent potential variability due to stromal cell contamination, we reanatance.
lyzed the same cohort following laser-capture microdissection (LCM) of tumor cells within each tissue section (Bonner et al., Results 1997; Emmert-Buck et al., 1996; Ma et al., 2003) . Using variance-based gene filtering and t test screening identical to that Identification of differentially expressed genes To identify gene expression patterns in hormone receptor-posiutilized for the whole tissue section dataset, we identified 9 differentially expressed genes with p Ͻ 0.001 ( Figure 1B ; Suptive, early-stage invasive breast cancers that might predict response to hormonal therapy, we performed microarray gene plemental Table S3 ). Three genes were identified as differentially expressed in both the LCM and whole tissue section analyses: expression analysis of tumors from 60 women uniformly treated with adjuvant tamoxifen alone. These patients were identified the homeobox gene HOXB13 (identified twice as AI700363 and BC007092), the interleukin 17B receptor IL17BR (AF208111), from a total of 103 ER-positive early-stage cases presenting to Massachusetts General Hospital between 1987 and 1997, from and EST AI240933 (Figure 1 ). HOXB13 was overexpressed in tamoxifen recurrence cases, whereas IL17BR and AI240933 whom tumor specimens were snap-frozen and for whom minimal 5-year follow-up was available (see Table 1 and Supplewere overexpressed in tamoxifen nonrecurrence cases.
Based on their identification as tumor-derived markers sigmental Table S1 at http://www.cancercell.org/cgi/content/full/ 5/6/607/DC1 for details). Within this cohort, 28 (46%) women nificantly associated with clinical outcome in two independent analyses, we evaluated the prognostic utility of each of these developed distant metastasis with a median time to recurrence of 4 years ("tamoxifen recurrences") and 32 (54%) women rethree genes by itself and in combination with the others. To define the sensitivity and specificity of HOXB13, IL17BR, and mained disease-free with median follow-up of 10 years ("tamoxifen nonrecurrences"). Recurrence cases were matched with AI240933 expression as biomarkers of clinical outcome, we used Receiver Operating Characteristic (ROC) analysis (Pepe, nonrecurrence cases with respect to TNM staging (Singletary et al., 2002) and tumor grade (Dalton et al., 2000) . 2000). For data derived from whole tissue sections, the Area Under the Curve (AUC) values for IL17BR, HOXB13, and Gene expression profiling was performed using a 22,000-gene oligonucleotide microarray. In the initial analysis, we iso-AI240933 were 0.79, 0.67, and 0.81, respectively (Table 2 ; Supplemental Figure S1 ). ROC analysis of the data generated from lated RNA from frozen tumor-tissue sections taken from the , 1980) . Therefore, mRNA measurements for ER and PR are all significantly greater than 0.5, the expected value from based on the microarray datasets were used to assess their the null model that predicts clinical outcome randomly (Table 2) .
predictive capacity for tamoxifen treatment outcome. In addiTherefore, these three genes have potential utility for predicting tion, growth factor signaling pathways (EGFR, ERBB2) are clinical outcome of patients treated with adjuvant tamoxifen.
thought to negatively regulate estrogen-dependent signaling, As comparison, we analyzed markers that are currently useand hence contribute to loss of responsiveness to tamoxifen ful in evaluating the likelihood of response to tamoxifen. All (Dowsett, 2001; Lichtner, 2003; Nicholson et al., 2003 ; Osborne but one of the 60 cases were ERϩ according to clinical tests and Schiff, 2003) . ROC analysis of the gene expression levels performed at diagnosis (Supplemental Table S1 ), but this binary of these genes confirmed their correlation with clinical outcome, receptor status is not informative for potential differences in but with AUC values ranging only from 0.55 to 0.69, reaching response to tamoxifen when essentially all patients are ERϩ.
statistical significance for PGR and ERBB2 (Table 2) . The LCM The quantitative levels of ER (gene symbol ESR1) and progesterdataset is particularly relevant, since EGFR, ERBB2, ESR1, and one receptor (PR, gene symbol PGR) are known to be positively PGR are currently measured at the tumor cell level using either immunohistochemistry or fluorescence in situ hybridization. As individual markers of clinical outcome, HOXB13, IL17BR, and AI240933 outperformed ESR1, PGR, EGFR, and ERBB2 (Table 2) . analysis of all three markers together did not provide additional that the expression ratio of HOXB13:IL17BR is a strong indepenpower (data not shown). dent predictor of treatment outcome in the setting of adjuvant We compared the HOXB13:IL17BR ratio to well-established tamoxifen therapy. prognostic factors for breast cancer, such as patient age, tumor size, grade, and lymph node status (Fitzgibbons et al., 2000) .
Independent validation of HOXB13:IL17BR expression Univariate logistic regression analysis indicated that only tumor ratio to predict tamoxifen treatment outcome size was marginally significant in this cohort (p ϭ 0.04); this was
The reduction of a complex microarray signature to a two-gene not surprising given that the nonrecurrence group was closely expression ratio allows the use of simpler detection strategies, matched to the recurrence group with respect to tumor size, such as real-time quantitative PCR (RT-QPCR) analysis. We tumor grade, and lymph node status during patient selection.
therefore analyzed the HOXB13:IL17BR expression ratio by RTAmong the known positive (ESR1 and PGR) and negative QPCR using tissue sections that were available from 59 of the (ERBB2 and EGFR) predictors of tamoxifen response, ROC 60 frozen specimens ( Figure 2A ). RT-QPCR data were highly analysis of the tissue sections data indicated that only PGR concordant with the microarray data of frozen tumor specimens and ERBB2 were significant (Table 2) . Therefore, we compared (Pearson correlation coefficient r ϭ 0.83 for HOXB13, 0.93 for logistic regression models containing the HOXB13:IL17BR ratio IL17BR). In addition, the PCR-derived HOXB13:IL17BR ratios, either by itself or in combination with tumor size, and expression represented as ⌬C T s, where C T is the PCR amplification cycles levels of PGR and ERBB2 (Table 4 ). The HOXB13:IL17BR ratio to reach a predetermined threshold amount (e.g., Figures 2A alone was a highly significant predictor (p ϭ 0.0003) and had and 2B) and ⌬C T is the C T difference between HOXB13 and an odds ratio of 10.2 (95% CI 2.9-35.6). In the multivariate IL17BR, were highly correlated with the microarray-derived data model, HOXB13:IL17BR ratio is the only significant variable (p ϭ (r ϭ 0.83) and with treatment outcome (t test p ϭ 5.8e-06, Figure  0 .002) with an odds ratio of 7.3 (95% CI 2.1-26). Controlling 2C). Thus, conventional RT-QPCR analysis for the expression for tumor size, tumor grade, and nodal status in patient selection ratio of HOXB13 to IL17BR appears to be equivalent to microis an effective strategy to reveal potential gene expression patarray-based analysis of frozen tumor specimens. terns predicting clinical outcome independent of known progOne significant benefit of using a simple two-gene ratio test nostic factors (Gruvberger et al., 2003) . However, the relative is the possibility of applying the test in routine clinical specipredictive power of HOXB13:IL17BR in the context of these mens, which are mostly formalin-fixed and paraffin-embedded known prognostic factors will need to be assessed in larger (FFPE) . To demonstrate the predictive utility of the HOXpopulation-based patient cohorts. The inclusion of only 10 PR-B13:IL17BR expression ratio in an independent patient cohort of negative patients may also underestimate the predictive utility FFPE specimens, we identified 20 additional ER-positive earlyof PR in this cohort. Nonetheless, these results demonstrated stage primary breast tumors from women treated with adjuvant tamoxifen monotherapy between 1991 and 2000, for whom both medical records and FFPE blocks were available. Of the 20 archival cases, 10 had recurred with a median time to recurrence ( Figure 2D ). To test the predictive accuracy of the HOXB13:IL17BR ratio, we used the RT-QPCR data from the frozen tissue sections (n ϭ positive and negative predictive values were 81% and 82%, the FFPE cohorts ( Figures 2E and 2F) . Therefore, the HOX-B13:IL17BR ratio model defined in the frozen cohort had comparable performance in an independent set of 20 FFPE cases, suggesting the potential of this two-gene ratio as an accurate predictive biomarker of clinical outcome for tamoxifen monotherapy.
HOXB13 stimulates mammary epithelial cell migration and invasion
The reduction of our tamoxifen response signature to two genes raised the possibility that these genes may not only be markers of clinical outcome but may be involved in breast tumorigenesis. Little information exists in the literature linking IL17BR to breast cancer. In contrast, HOXB13 has been shown to be overexpressed in a small number of breast cancer tissue samples (n ϭ 11) (Cantile et al., 2003) . Indeed, RT-QPCR analysis of LCMprocured normal and malignant breast epithelial cells from our expanded, previously published cohort (n ϭ 45) (Ma et al., 2003) demonstrated that compared to normal breast epithelial cells, the mean expression levels of HOXB13 were significantly higher in both ductal carcinoma in situ (DCIS, p ϭ 0.002) and invasive ductal carcinoma (IDC, p ϭ 0.006) ( Figure 3A ). Compared to patient-matched normals, 56% DCIS or IDC cases overexpressed HOXB13 by Ͼ2-fold. Furthermore, RNA in situ hybridization confirmed the tumor cell-specific expression of HOXB13 ( Figure 3B ). Interestingly, a subset of normal breast specimens demonstrated expression of HOXB13 in terminal duct lobular unit, raising the possibility that it may play a role in normal mammary physiology ( Figure 3B ).
To investigate the potential biological function of HOXB13, we expressed a retroviral construct in MCF-10A cells, a nontransformed human mammary epithelial cell line spontaneously 
lial-type junctions (data not shown). Compared to cells infected FFPE sections (D). In each plot, the dashed line denotes the cutoff point
with the empty vector, MCF10A cells expressing HOXB13 had determined by logistic regression analysis; numerals represent the number of nonrecurrences and recurrences.
a 5-fold increase in cell motility in trans-well migration assays E and F: Kaplan-Meier disease-free survival curves for the frozen (E) and in the presence of EGF ( Figure 3C ). Invasion through a Matrigel-FFPE (F) cohorts comparing patients with HOXB13:IL17BR ratios above (high coated modified Boyden chamber, a well-established assay H:I) or below (low H:I) the cutoff point defined in the logistic regression correlated with metastatic potential in vivo (Albini et al., 1987;  model. Repesh, 1989) , was also enhanced 5-fold by HOXB13 expression in the presence of EGF ( Figure 3D ). These observations suggest that HOXB13 may regulate a pathway that functions synergistically with EGF-dependent signaling to stimulate cell respectively (the cutoff point derived from the model was indimotility and invasion in vitro. cated by the dashed line in Figure 2C ). Because we identified the two genes and built the model in the same patient cohort, Discussion these performance estimates may be biased. Therefore, we applied the model directly to the 20 independent patients in the Previous studies linking gene expression profiles to clinical out-FFPE cohort. In the resulting "honest" prediction, treatment come in breast cancer have demonstrated that the potential outcome for 16 of the 20 patients was correctly predicted with an overall accuracy of 80% and positive and negative predictive for distant metastasis and overall survival probability may be attributable to biological characteristics of the primary tumor at values of 87% and 75%, respectively ( Figure 2D ). The probability of correctly predicting 16 of 20 cases by chance was 0.01 (exact the time of diagnosis (Huang et al., 2003; Sorlie et al., 2001 Sorlie et al., , 2003 Sotiriou et al., 2003; van de Vijver et al., 2002; t Veer binomial test; 95% confidence interval 56%-94%), demonstrating the statistical significance of the two-gene ratio test in the et al., 2002) . In particular, a 70-gene expression signature has proven to be a strong prognostic factor, outperforming all known independent FFPE cohort. To further illustrate the predictive ability of HOXB13:IL17BR ratio, the two patient groups stratified clinicopathological parameters. However, in those studies, patients either received no adjuvant therapy (van 't Veer et al., by the HOXB13:IL17BR ratio cutoff point exhibited significantly different disease-free survival curves in both the frozen and 2002) or were treated nonuniformly with hormonal and chemo- , 2003) . However, the published cDNA microarray dataset did not include HOXB13 or IL17BR. Even when all 25 fen alone, such as the cohorts studied here, represent only a subset of the population tested with the 70-gene signature. Of genes identified in this study ( Figures 1A and 1B) were considered, only two genes (IL1R2 and APS) were present on their note, 61 of the genes in the 70-gene signature were present on the microarray used in our study, but no significant association cDNA microarray, making it impossible to evaluate our predictive signature. with clinical outcome was observed in our patient cohorts (data not shown). Conversely, the HOXB13:IL17BR ratio identified in
The observation that a simple expression ratio of two genes, HOXB13:IL17BR, accurately predicts tumor recurrence in adjuour tamoxifen-treated cohorts is not effective in predicting clinical outcome of patients receiving no adjuvant therapy in the vant tamoxifen-treated patients with early-stage ER-positive breast cancer is limited by the size of patient cohorts in this van 't Veer study (data not shown). Hence, the genes identified here as correlated with clinical outcome in the setting of adjuvant study and will require confirmation in a larger population-based cohort. Furthermore, it remains to be determined whether this tamoxifen monotherapy may differ from those associated with inherent biological properties of a more diverse collection of two-gene ratio predicts a tumor's response to tamoxifen or its intrinsic aggressiveness, or both. A similarly case-matched breast cancers. We also attempted to evaluate our two-gene fying patients who may benefit from more complete ablation of Patient inclusion criteria for this study were: women diagnosed at the Massaestrogen signaling using aromatase inhibitors (Goss et al., 2003) chusetts (Dalton et al., 2000) . Estrogen and progesterone receptor 1993). However, expression of HOXC8 was recently shown to expression were determined by biochemical hormone binding analysis and/ be upregulated in prostate cancer and to suppress androgen or by immunohistochemical staining as described (Harvey et al., 1999) . More receptor signaling (Miller et al., 2003) , raising the possibility that specifically, ER positivity was defined as greater than 10 fmol/mg tumor tissue and greater than 1% nuclear staining or immunohistochemistry (IHC) some homeobox genes may interact with hormone receptor score of at least 3 for the biochemical and immunohistochemical assays signaling. Consistent with a previous report (Cantile et al., 2003) , (Harvey et al., 1999) , respectively; all but three tumors (2 recurrences and we demonstrated that HOXB13 was frequently upregulated in context of tamoxifen resistance, since activation of growth factor signaling pathways can cause tamoxifen-resistant tumor LCM and RNA isolation and amplification growth (Clarke et al., 2003; Nicholson et al., 1994; With each frozen tumor sample within the 60-case cohort, RNA was isolated Schiff, 2003) . Given the known role of ERBB2 overexpression in regulation (Chakravarti et al., 1996; Hanstein et al., 1996) . Therefore, HOXB13 may be involved directly and indirectly in the was achieved by subtracting the median log2 ratios gene-wise across all packaging cells as described (Ory et al., 1996) , and stable pools of MCF-10A cells were generated by retroviral infection as described (Debnath et arrays. The variance of each gene over all samples was calculated and the top 25% high variance genes (5,475) selected for further analysis. Identificaal., 2003) using 2 g/ml puromycin for selection. Control cells were MCF10 cells infected with the empty pBABE vector. tion and permutation testing for significance of differential gene expression were performed using BRB ArrayTools, developed by Richard Simon and Amy Peng (http://linus.nci.nih.gov/BRB-ArrayTools.html). Hierarchical clusTrans-well migration and invasion assay In vitro migration and invasion assays were performed using 24-well modified ter analysis was performed with GeneMaths software (Applied-Maths, Belgium) using cosine correlation as distance and complete linkage clustering.
Boyden chamber trans-well with PET (polyethylene terephthalate) membranes containing 8 micron pores (BD BioCoat). Uncoated membranes were All other statistical procedures (two-sample t test, receiver operating characteristic analysis, logistic regression, and survival analysis) were performed used for migration assays, and Matrigel-coated membranes were used for invasion (Repesh, 1989) . Stable pools of MCF-10A cells infected with retroviin the open-source R statistical environment (http://www.r-project.org). Staral constructs were maintained in growth medium until the day of the assay. tistical test of significance of ROC curves was by the method of DeLong et 5 ϫ 10 4 cells in 100 l of assay medium were seeded in the upper chamber, al. (1988) as implemented by Doug Mahoney and Beth Atkinson in their and 500 l assay medium with or without 20 ng/ml EGF was added to the S-Plus roc package (http://www.mayo.edu/hsr/Sfunc.html). Disease-free lower chamber. Cells were incubated at 37ЊC for 24 hr, then fixed in 70% survival was calculated from the date of diagnosis. Events were scored as ethanol for 20 min, rinsed with PBS, and stained with DAPI (500 ng/ml). the first distant metastasis, and patients remaining disease-free at the last Cells that remained on the upper surface were mechanically removed with follow-up were censored. Survival curves were calculated by the Kaplana cotton swab. Cells remaining on the underside were counted (5 fields at Meier estimates and compared by log-rank tests. To build a predictive model 20ϫ magnification per trans-well). Trans-wells were plated in triplicates and using HOXB13 and IL17BR, raw C T values from RT-QPCR were normalized the results were averaged. Invasion through a Matrigel-coated modified across the sample set (subtracting the mean C T and dividing by the standard Boyden chamber was assayed as described (Albini et al., 1987; Repesh, deviation) , and the two-gene ratio was the difference of normalized C T values 1989). (HOXB13 Ϫ IL17BR); normalization was done separately for the frozen and FFPE cohorts. The two-gene ratio was then used in a univariate logistic
